Form 4: Krystal Biotech President Sells Shares
Insider Transaction (Form 4)
Suma Krishnan, President, R&D, a Director and 10% owner of Krystal Biotech, Inc., sold 25,000 shares of common stock on September 4, 2026.
Summary
- Open-market sale: disposed of 520 Common Stock at $354.54 ($184,361) on September 4, 2026; holds 1,326,625 after (Direct).
- Open-market sale: disposed of 2,006 Common Stock at $355.57 ($713,277) on September 4, 2026; holds 1,324,619 after (Direct).
- Open-market sale: disposed of 3,267 Common Stock at $356.37 ($1,164,254) on September 4, 2026; holds 1,321,352 after (Direct).
- Open-market sale: disposed of 3,962 Common Stock at $357.57 ($1,416,709) on September 4, 2026; holds 1,317,390 after (Direct).
- Open-market sale: disposed of 3,180 Common Stock at $358.42 ($1,139,777) on September 4, 2026; holds 1,314,210 after (Direct).
- Open-market sale: disposed of 3,392 Common Stock at $359.39 ($1,219,038) on September 4, 2026; holds 1,310,818 after (Direct).
- Open-market sale: disposed of 2,320 Common Stock at $360.47 ($836,281) on September 4, 2026; holds 1,308,498 after (Direct).
- Open-market sale: disposed of 1,242 Common Stock at $361.61 ($449,120) on September 4, 2026; holds 1,307,256 after (Direct).
- Open-market sale: disposed of 1,992 Common Stock at $362.65 ($722,404) on September 4, 2026; holds 1,305,264 after (Direct).
- Open-market sale: disposed of 565 Common Stock at $363.34 ($205,287) on September 4, 2026; holds 1,304,699 after (Direct).
- Open-market sale: disposed of 1,329 Common Stock at $364.48 ($484,390) on September 4, 2026; holds 1,303,370 after (Direct).
- Open-market sale: disposed of 826 Common Stock at $365.41 ($301,832) on September 4, 2026; holds 1,302,544 after (Direct).
- Open-market sale: disposed of 399 Common Stock at $366.56 ($146,256) on September 4, 2026; holds 1,302,145 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $8,982,986 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Suma Krishnan — Director, Officer (President, R&D), 10% owner
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-04 | Open-market sale | Common Stock | 520 | $355 | $184.4K | 1,326,625 |
| 2026-09-04 | Open-market sale | Common Stock | 2,006 | $356 | $713.3K | 1,324,619 |
| 2026-09-04 | Open-market sale | Common Stock | 3,267 | $356 | $1.2M | 1,321,352 |
| 2026-09-04 | Open-market sale | Common Stock | 3,962 | $358 | $1.4M | 1,317,390 |
| 2026-09-04 | Open-market sale | Common Stock | 3,180 | $358 | $1.1M | 1,314,210 |
| 2026-09-04 | Open-market sale | Common Stock | 3,392 | $359 | $1.2M | 1,310,818 |
| 2026-09-04 | Open-market sale | Common Stock | 2,320 | $360 | $836.3K | 1,308,498 |
| 2026-09-04 | Open-market sale | Common Stock | 1,242 | $362 | $449.1K | 1,307,256 |
| 2026-09-04 | Open-market sale | Common Stock | 1,992 | $363 | $722.4K | 1,305,264 |
| 2026-09-04 | Open-market sale | Common Stock | 565 | $363 | $205.3K | 1,304,699 |
| 2026-09-04 | Open-market sale | Common Stock | 1,329 | $364 | $484.4K | 1,303,370 |
| 2026-09-04 | Open-market sale | Common Stock | 826 | $365 | $301.8K | 1,302,544 |
| 2026-09-04 | Open-market sale | Common Stock | 399 | $367 | $146.3K | 1,302,145 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-04 | Open-market sale (520 shares) |
| 2026-09-04 | Open-market sale (2,006 shares) |
| 2026-09-04 | Open-market sale (3,267 shares) |
| 2026-09-04 | Open-market sale (3,962 shares) |
| 2026-09-04 | Open-market sale (3,180 shares) |
| 2026-09-04 | Open-market sale (3,392 shares) |
| 2026-09-04 | Open-market sale (2,320 shares) |
| 2026-09-04 | Open-market sale (1,242 shares) |
| 2026-09-04 | Open-market sale (1,992 shares) |
| 2026-09-04 | Open-market sale (565 shares) |
| 2026-09-04 | Open-market sale (1,329 shares) |
| 2026-09-04 | Open-market sale (826 shares) |
| 2026-09-04 | Open-market sale (399 shares) |
Keywords
insider transaction, Form 4, KRYS, Krystal Biotech, Inc., bearish, Suma Krishnan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.